Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIHS-I: Plasma with Anti-IFN-1 Autoantibodies for Severe HS
NCT07067099Phase 1Not yet recruiting
- Sponsor
- CHU de Besançon
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in hidradenitis suppurativa (HS), sponsored by CHU de Besançon. Primary endpoint: Safety of transfusion of plasma containing high titer anti-IFN-1 auto-Antibodies at 28 days. Planned start Sep 2025; status: not yet recruiting.
02
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07067099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07067099.